Acceleron presents ACE-041 interim results for advanced cancer in EORTC-NCI-AACR Symposium Acceleron Pharma, Inc., a biopharmaceutical organization developing novel protein therapeutics that regulate the development and growth of cells and cells, including muscle, bone, reddish blood cells, and vasculature, today announced the presentation of interim outcomes from the first-in-human scientific study of ACE-041 in sufferers with advanced cancer at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Berlin, Germany. The presentation was presented with by Professor Sunil Sharma, the Jon and Karen Huntsman Presidential Professor of Malignancy Analysis at the Huntsman Malignancy Institute, University of Utah, Salt Lake City, Utah.Investigators hosted group-specific training teleconferences at least regular monthly to discuss execution, compliance, and any new, potentially conflicting initiatives. Compliance assessment involved verification on 1 day per week for each ICU. HCA leadership evaluated trial procedures during routine hospital appointments. Additional site visits were made at the demand of a healthcare facility or if compliance was discovered to be low. All mupirocin and chlorhexidine-impregnated cloths had been purchased at their usual price by the participating hospitals.